Advancing personalized immunotherapy for hard-to-treat solid tumors
Our research integrates personalized neoantigen screening and validation with dendritic cell therapy to address the heterogeneity of challenging solid tumors.
Ovarian cancerPancreatic cancerProstate cancerGlioblastoma